New Research: Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and Benefit: Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer with a poor prognosis and… https://t.co/
Check out our recent (two) papers published in @FrontImmunol about the selection and pre-clinical study of a AFP-targeting TCR for #immunotherapy (ACT) of liver cancer, and thanks @humanimmunenews for picking it up!
Researchers evaluated the efficacy and safety profile of 7 #TCellReceptors by testing their potency toward alpha-fetoprotein-expressing hepatocellular carcinoma cells. @GACancerCenter https://t.co/6l9MSrpuov https://t.co/gkOCekXcnL